2510-37-4 Usage
Uses
Used in Pharmaceutical Industry:
2,4-Dimethyl-1,3-oxazole-5-carboxylic acid is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its unique structure allows it to be a key component in the synthesis of human phosphodiesterases (PDE) 5 inhibitors, such as sildenafil analogs. These inhibitors play a crucial role in treating erectile dysfunction and other related conditions by enhancing blood flow to the affected areas.
Used in Trypanosomal PDE Inhibitors:
In addition to its application in the synthesis of PDE 5 inhibitors, 2,4-Dimethyl-1,3-oxazole-5-carboxylic acid is also utilized as a reagent in the development of trypanosomal PDE inhibitors. These inhibitors are essential in the treatment of trypanosomiasis, a parasitic disease caused by the protozoan parasites of the genus Trypanosoma. By targeting and inhibiting specific PDEs, these compounds can help combat the infection and alleviate its symptoms.
Check Digit Verification of cas no
The CAS Registry Mumber 2510-37-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,5,1 and 0 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 2510-37:
(6*2)+(5*5)+(4*1)+(3*0)+(2*3)+(1*7)=54
54 % 10 = 4
So 2510-37-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H7NO3/c1-3-5(6(8)9)10-4(2)7-3/h1-2H3,(H,8,9)
2510-37-4Relevant academic research and scientific papers
Formation of 6-Azaindoles by Intramolecular Diels-Alder Reaction of Oxazoles and Total Synthesis of Marinoquinoline A
Jhaveri, Dishit P.,Osano, Mana,Wipf, Peter
supporting information, p. 2215 - 2219 (2020/04/09)
A new variant of the intramolecular Diels-Alder oxazole (IMDAO) cycloaddition that provides direct access to 6-azaindoles was developed. The IMDAO reaction was applied in a total synthesis of the aminophenylpyrrole-derived alkaloid marinoquinoline A, also
Gonadotropin releasing hormone receptor antagonists
-
Page/Page column 22-23, (2010/02/15)
The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.
